Axsome Therapeutics, Inc. (0HKF.L)
0HKF.L Stock Price Chart
Explore Axsome Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze 0HKF.L price movements and trends.
0HKF.L Company Profile
Discover essential business fundamentals and corporate details for Axsome Therapeutics, Inc. (0HKF.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
712.00
Website
https://www.axsome.comCEO
Herriot Tabuteau
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
0HKF.L Financial Timeline
Browse a chronological timeline of Axsome Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 16 Feb 2026
Upcoming earnings on 10 Nov 2025
Earnings released on 4 Aug 2025
EPS came in at -$0.97 surpassing the estimated -$1.06 by +8.06%, while revenue for the quarter reached $150.04M , missing expectations by -8.47%.
Earnings released on 5 May 2025
EPS came in at -$1.22 surpassing the estimated -$1.35 by +9.71%, while revenue for the quarter reached $121.46M , missing expectations by -13.51%.
Earnings released on 18 Feb 2025
EPS came in at -$1.54 falling short of the estimated -$1.00 by -54.17%, while revenue for the quarter reached $118.77M , missing expectations by -0.62%.
Earnings released on 12 Nov 2024
EPS came in at -$1.34 surpassing the estimated -$1.38 by +3.14%, while revenue for the quarter reached $103.74M , missing expectations by -12.04%.
Earnings released on 5 Aug 2024
EPS came in at -$1.67 falling short of the estimated -$1.31 by -27.59%, while revenue for the quarter reached $87.17M , beating expectations by +0.28%.
Earnings released on 6 May 2024
EPS came in at -$1.44 falling short of the estimated -$1.20 by -19.74%, while revenue for the quarter reached $75.00M , beating expectations by +2.33%.
Earnings released on 6 Mar 2024
EPS came in at -$2.08 falling short of the estimated -$1.17 by -77.94%, while revenue for the quarter reached $71.53M , beating expectations by +3.31%.
Earnings released on 6 Nov 2023
EPS came in at -$1.32 falling short of the estimated -$1.20 by -9.71%, while revenue for the quarter reached $57.79M , beating expectations by +5.33%.
Earnings released on 7 Aug 2023
EPS came in at -$1.54 falling short of the estimated -$1.21 by -26.75%, while revenue for the quarter reached $46.70M , beating expectations by +14.24%.
Earnings released on 8 May 2023
EPS came in at -$0.26 surpassing the estimated -$1.30 by +80.23%, while revenue for the quarter reached $94.58M , beating expectations by +271.31%.
Earnings released on 27 Feb 2023
EPS came in at -$1.41 falling short of the estimated -$1.13 by -25.19%, while revenue for the quarter reached $24.37M , beating expectations by +12.03%.
Earnings released on 30 Sept 2022
EPS came in at -$1.07 falling short of the estimated -$1.05 by -2.35%, while revenue for the quarter reached $16.85M , beating expectations by +1.26%.
Earnings released on 30 Jun 2022
EPS came in at -$1.06 falling short of the estimated -$1.01 by -5.39%, while revenue for the quarter reached $8.82M , beating expectations by +27.49%.
Earnings released on 31 Mar 2022
EPS came in at -$1.03 falling short of the estimated -$1.00 by -3.13%.
Earnings released on 31 Dec 2021
EPS came in at -$0.90 .
Earnings released on 30 Sept 2021
EPS came in at -$0.93 surpassing the estimated -$1.02 by +9.38%.
Earnings released on 30 Jun 2021
EPS came in at -$0.86 .
Earnings released on 31 Mar 2021
EPS came in at -$0.78 .
Earnings released on 31 Dec 2020
EPS came in at -$0.78 .
Earnings released on 30 Sept 2020
EPS came in at -$0.61 .
0HKF.L Stock Performance
Access detailed 0HKF.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.